Predictors of Disease Recurrence and Survival in Esophageal Adenocarcinomas With Complete Response to Neoadjuvant Therapy
Authors:
- Yifan ZhengYZYifan Zheng
- Raphael BuenoRBRaphael Bueno
- Gregory Y. LauwersGLGregory Y. Lauwers
- Robert D. OdzeRORobert D. Odze
- Amitabh SrivastavaASAmitabh Srivastava
- 1 August 2015
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 39 (8) , 1085-1092
Abstract
Complete response to neoadjuvant therapy, determined by pathologic examination of the resection specimen (pCR), is associated with a favorable outcome in esophageal adenocarcinomas (EAC), but there is significant heterogeneity in survival reported within this group. Our aim was to determine predictors of disease recurrence (DR) and survival in EAC patients with pCR to neoadjuvant therapy. A total of 93 EAC patients with pCR to neoadjuvant therapy were identified, and a predetermined set of clinicopathologic variables was examined, including patient age, sex, tumor location, pretreatment tumor size, endoscopic ultrasound T and N stage, histologic tumor type, and grade in pretreatment biopsies. The esophagectomy specimens were evaluated for the extent of sampling of the tumor bed, depth of treatment-related changes, presence of treatment effect in lymph nodes, and the total number of lymph nodes examined. Complete histologic examination of the tumor bed was the most significant predictor of favorable outcome for both DR (hazard ratio [HR]=0.42; 95% confidence interval [CI]: 0.21-0.82; P=0.011) and disease-specific mortality (HR=0.40; 95% CI: 0.22-0.70; P<0.01). The presence of a high-grade adenocarcinoma component in pretreatment biopsies (HR=2.19; 95% CI: 1.22-3.94; P<0.01) was associated with a higher disease-specific mortality, and involvement of the gastroesophageal junction (HR=2.37; 95% CI: 1.11-5.06; P=0.026) was associated with a higher rate of DR. Heterogeneity in outcomes for EAC patients with pCR to therapy can be explained by adequacy of histologic examination of the tumor bed, high tumor grade, and involvement of the gastroesophageal junction.Keywords
This publication has 30 references indexed in Scilit:
- Signet Ring Cells in Esophageal and Gastroesophageal Junction Carcinomas Have a More Aggressive Biological BehaviorAnnals of Surgery, 2014
- Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapyAnnals of Oncology, 2013
- Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohortAnnals of Oncology, 2012
- Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancerAnnals of Oncology, 2012
- The Prognostic Value of Clinical and Pathologic Factors in Esophageal Adenocarcinoma: A Mayo Cohort of 796 Patients With Extended Follow-up After Surgical ResectionMayo Clinic Proceedings, 2010
- Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomasLaboratory Investigation, 2009
- Long-term Outcomes Following Neoadjuvant Chemoradiotherapy for Esophageal CancerAnnals of Surgery, 2007
- Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagusCancer, 2005
- Complete Response to Neoadjuvant Chemoradiotherapy in Esophageal Carcinoma Is Associated With Significantly Improved SurvivalJournal of Clinical Oncology, 2005
- Surgical Pathology of Adenocarcinoma Arising in Barrettʼs Esophagus Analysis of 67 CasesAmerican Journal of Surgical Pathology, 1995